Page 1

Full Year 2020 Results Worldwide Increased $ 82.6B 0.6 % 2020 Sales Diluted Earnings Per Share Decreased $ 5.51 ( 2.1 ) % Excluding acquisitions / divestitures on an operational basis Worldwide Increased 1.5 % * Adjusted Diluted Earnings Per Share * Decreased $ 8.03 ( 7.5 ) % " Our notable full year performance reflects the continued confidence from patients , physicians , customers and consumers in our life - enhancing products and medicines , particularly throughout the COVID - 19 pandemic . I'm incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs . These efforts , and our commitment to families around the world as the largest broad - based healthcare company , enabled us to lead in the fight against COVID - 19 . We continue to progress our COVID - 19 vaccine candidate and look forward to sharing details from our Phase 3 study soon . Johnson & Johnson was built for times like these , and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come . " Alex Gorsky Chairman and Chief Executive Officer Johnson & Johnson $ 14.1 Billion Ô $ 45.6 Billion A $ 23.0 Billion aff Worldwide Consumer Health Sales Consumer Health worldwide reported sales increased 1.1 % or 3.0 % operationally ' . Primary operational drivers : TYLENOL LISTERINE BAND - AID Pepcid ogs ZARBEE'S Aveeno . ZYRTEC NATURALE Worldwide Pharmaceutical Sales Pharmaceutical worldwide reported sales increased 8.0 % or 8.2 % operationally . Primary operational drivers : Johnson & Johnson Stelara DARZALEX imbruvica Tremfya Erleada stenume Prin Uptravi MEGA SUSTENNA Electrophysiology Symtuza war a Opsumit maclantan Worldwide Medical Devices Sales Medical Devices worldwide reported sales decreased ( 11.6 ) % or ( 11.4 ) % operationally . Offsets to decline : Juluca bungano Neurovascular Note : values may have been rounded For full financial data and non - GAAP reconciliations , please refer to Johnson & Johnson's earnings release issued on January 26 , 2021 , available at http://www.investor.jnj.com/sales-earnings.cfm . * Non - GAAP financial measure , non - GAAP financial measures should not be considered replacements for , and should be read together with , the most comparable GAAP financial measures . ' Non - GAAP measure ; excludes the impact of translational currency . Caution Concerning Forward - Looking Statements : This document contains " forward - looking statements " as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance . You are cautioned not to rely on these forward - looking statements , which are based on current expectations of future events . For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions , expectations , and projections expressed in any forward - looking statements , review the " Note to Investors Concerning Forward - Looking Statements included in the Johnson & Johnson earnings release issued on January 26 , 2021 , as well as the most recently filed Johnson & Johnson Reports on Forms 10 - K and 10 - Q . Johnson & Johnson does not undertake to update any forward - looking statement as a result of new information or future events or developments .